Surrozen logo

SurrozenNASDAQ: SRZN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

11 January 2021

Next earnings report:

08 May 2025

Last dividends:

N/A

Next dividends:

N/A
$28.89 M
-91%vs. 3y high
28%vs. sector
-vs. 3y high
-vs. sector
-34%vs. 3y high
83%vs. sector
-34%vs. 3y high
47%vs. sector

Price

after hours | Wed, 20 Nov 2024 22:01:53 GMT
$8.89-$1.27(-12.50%)

Dividend

No data over the past 3 years
$10.00 M-$1.43 M

Analysts recommendations

Institutional Ownership

SRZN Latest News

Surrozen to Present at Upcoming Healthcare Investor Conferences
globenewswire.com06 November 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Craig Parker, President and Chief Executive Officer, will present at two upcoming healthcare investor conferences.

Surrozen Provides Third Quarter 2024 Financial Results and Business Update
globenewswire.com06 November 2024 Sentiment: POSITIVE

Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 2025 Nominated novel portfolio of preclinical ophthalmology product candidates to R&D pipeline Received $10 million milestone payment from Boehringer Ingelheim strategic collaboration on SZN-413 in retinal vascular associated diseases SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided third quarter 2024 financial results and business updates.

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
globenewswire.com10 June 2024 Sentiment: POSITIVE

SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis Phase 1a trial of SZN-043 demonstrated evidence of target engagement and Wnt-pathway mediated pharmacodynamic effects in the liver Enrollment is ongoing in Phase 1b study in severe alcohol-associated hepatitis SOUTH SAN FRANCISCO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, presented a poster on the preliminary results of a Phase 1a study of SZN-043, a novel R-Spondin mimetic, in healthy volunteers and subjects with liver cirrhosis on June 8, 2024 at the 2024 European Association for the Study of the Liver (EASL) in Milan (LINK: HERE).

Here's Why Surrozen, Inc. (SRZN) Could be Great Choice for a Bottom Fisher
Zacks Investment Research08 May 2023 Sentiment: POSITIVE

Surrozen, Inc. (SRZN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

What type of business is Surrozen?

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

What sector is Surrozen in?

Surrozen is in the Healthcare sector

What industry is Surrozen in?

Surrozen is in the Biotechnology industry

What country is Surrozen from?

Surrozen is headquartered in United States

When did Surrozen go public?

Surrozen initial public offering (IPO) was on 11 January 2021

What is Surrozen website?

https://www.surrozen.com

Is Surrozen in the S&P 500?

No, Surrozen is not included in the S&P 500 index

Is Surrozen in the NASDAQ 100?

No, Surrozen is not included in the NASDAQ 100 index

Is Surrozen in the Dow Jones?

No, Surrozen is not included in the Dow Jones index

When was Surrozen the previous earnings report?

No data

When does Surrozen earnings report?

The next expected earnings date for Surrozen is 08 May 2025